Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse

References

• van Gestel YRBM, de Hingh IHJT, van Herk-sukel MPP, van Erning FN, Beerepoot LV, Wijsman JH, Slooter GD, Rutten HJT, Creemers GJM, Lemmens VEPP. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. Elsevier Ltd. 2014;38(4):448–12. doi:10.1016/j.canep.2014.04.004.
   PubMed Web of Science ®Google Scholar
• Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology. 2003;50:1362–1366. http://www.ncbi.nlm.nih.gov/pubmed/14571738.
   PubMedGoogle Scholar
• Eisenberg B, Decosse JJ, Harford F, Michalek J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982;49:1131–1134. doi:10.1002/1097-0142(19820315)49:6<1131::AID-CNCR2820490611>3.0.CO;2-T.
   PubMed Web of Science ®Google Scholar
• Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, Derchi L, Ferraris R. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002;28:418–423. doi:10.1053/ejso.2001.1250.
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–2666. doi:10.1056/NEJMoa051424.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Van Den Eynde M, Bindea G, Church SE, Vasaturo A, et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. 2017 [accessed 2019 Jan 10]. https://academic.oup.com/jnci/article-abstract/110/1/97/4093937
   Google Scholar
• Rozek LS, Schmit SL, Greenson JK, Tomsho LP, Rennert HS, Rennert G, Gruber SB. Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. JNCI J Natl Cancer Inst. Oxford University Press. 2016;108. doi:10.1093/jnci/djw027.
   Web of Science ®Google Scholar
• Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Nelson HH, Lynch CF, Pengo T, Thibodeau SN, Church TR, Cerhan JR. Cytotoxic T cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev. 2017;26:622–631. doi:10.1158/1055-9965.EPI-16-0641.
   PubMed Web of Science ®Google Scholar
• Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:350–366. doi:10.1002/path.2774.
   PubMed Web of Science ®Google Scholar
• Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–78. doi:10.1038/nrc1256.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499. doi:10.1038/nature22396.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell Cell Press. 2019;35(4):588–602.e10. doi:10.1016/j.ccell.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–1356. doi:10.1038/nm.3967.
   PubMed Web of Science ®Google Scholar
• Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. NIH Public Access. 2011;17:528–536. doi:10.1097/PPO.0b013e318238216e.
   PubMed Web of Science ®Google Scholar
• Kamal Y, Schmit SL, Hoehn HJ, Amos CI, Frost HR. Transcriptomic differences between primary colorectal adenocarcinomas and distant metastases reveal metastatic colorectal cancer subtypes. Cancer Res. 2019 [cited 2019 Jun 27]:canres.3945.2018. http://www.ncbi.nlm.nih.gov/pubmed/31239274
   PubMed Web of Science ®Google Scholar
• Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E, et al. Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009;106:7131–7136. doi:10.1073/pnas.0902232106.
   PubMed Web of Science ®Google Scholar
• Sanz-Pamplona R, Cordero D, Berenguer A, Lejbkowicz F, Rennert H, Salazar R, Biondo S, Sanjuan X, Pujana MA, Rozek L, et al. Gene expression differences between colon and rectum tumors. Clin Cancer Res. 2011;17:7303–7312. doi:10.1158/1078-0432.CCR-11-1570.
   PubMed Web of Science ®Google Scholar
• Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi M-C, Schiappa R, Guenot D, Ayadi M, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. Public Library of Science. 2013;10:e1001453. doi:10.1371/journal.pmed.1001453.
   PubMed Web of Science ®Google Scholar
• Varn FS, Andrews EH, Mullins DW, Cheng C. Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. Nat Commun. 2016;7:10248. doi:10.1038/ncomms10248.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. BioMed Central Ltd. 2016;17:218. doi:10.1186/s13059-016-1070-5.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdó H, Ghandi M, Mesirov JP, et al. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1:417–425. doi:10.1016/j.cels.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, Huang Q, Shi X, Ni Z, Ding N, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol. Frontiers Media S.A. 2019;10:2368. PMID: 31681276; PMCID: PMC6811516. doi: 10.3389/fimmu.2019.02368..
   Web of Science ®Google Scholar
• Ouzounova M, Lee E, Piranlioglu R, El Andaloussi A, Kolhe R, Demirci MF, Marasco D, Asm I, Chadli A, Hassan KA, et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat Commun. 2017;8:14979. doi:10.1038/ncomms14979.
   PubMed Web of Science ®Google Scholar
• Cafri G, Yossef R, Pasetto A, Deniger DC, Lu Y-C, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun. 2019;10:449. doi:10.1038/s41467-019-08304-z.
   PubMed Web of Science ®Google Scholar
• Becht E, De Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P, Fridman WH, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. American Association for Cancer Research Inc. 2016;22:4057–4066. doi:10.1158/1078-0432.CCR-15-2879.
   PubMed Web of Science ®Google Scholar
• Karpinski P, Rossowska J, Sasiadek MM. Immunological landscape of consensus clusters in colorectal cancer. Oncotarget. 2017;8:105299–105311. doi:10.18632/oncotarget.22169.
   PubMedGoogle Scholar
• Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science. 2018;362:eaar3593. doi:10.1126/science.aar3593.
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Buchberger B, Pox C, Graeven U, Holch JW, Schmiegel W, Heinemann V. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Eur J Cancer. 2019;106:37–44. doi:10.1016/j.ejca.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Disis ML, Fox BA, Kaufman DR, Khleif SN, Wang E. SITC 2018 workshop report: immuno-oncology biomarkers: state of the art. J Immunother Cancer. BioMed Central. 2018;6:138. doi:10.1186/s40425-018-0453-4.
   PubMed Web of Science ®Google Scholar